Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study
IntroductionLong COVID is a public health issue with complex pathophysiology, potentially involving immunoinflammatory and prothrombotic mechanisms. Antiphospholipid antibodies (aPL) have been observed in acute COVID-19 and speculated to contribute to long COVID development. Our goal was to determin...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1634663/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850039446552969216 |
|---|---|
| author | Robin Arcani Robin Arcani Alexandre Brodovitch Xavier Heim Xavier Heim Jean-Louis Mège Jean-Louis Mège Nathalie Bardin Nathalie Bardin |
| author_facet | Robin Arcani Robin Arcani Alexandre Brodovitch Xavier Heim Xavier Heim Jean-Louis Mège Jean-Louis Mège Nathalie Bardin Nathalie Bardin |
| author_sort | Robin Arcani |
| collection | DOAJ |
| description | IntroductionLong COVID is a public health issue with complex pathophysiology, potentially involving immunoinflammatory and prothrombotic mechanisms. Antiphospholipid antibodies (aPL) have been observed in acute COVID-19 and speculated to contribute to long COVID development. Our goal was to determine if the presence of aPL was associated with the progression towards long COVID.MethodsWe retrospectively analyzed all adult patients screened for aPL during acute COVID-19 in our institution between April 2020 and April 2022. Only patients with at least one follow-up ≥3 months post-infection were included.ResultsAmong 114 patients (median age 64.0 years, 44.7% female), 19 (16.7%) developed long COVID. Those with long COVID were younger and more frequently admitted to ICU than those who recovered. However, aPL positivity did not differ significantly between patients with and without long COVID (63.2% vs. 66.3%, p = 0.79).ConclusionOur findings suggest no association between aPL and the development of long COVID. Prior associations may reflect confounding factors such as ICU admission. |
| format | Article |
| id | doaj-art-f5c0b9cfcc624f6cb6fb134ed86a2bdb |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-f5c0b9cfcc624f6cb6fb134ed86a2bdb2025-08-20T02:56:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16346631634663Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort studyRobin Arcani0Robin Arcani1Alexandre Brodovitch2Xavier Heim3Xavier Heim4Jean-Louis Mège5Jean-Louis Mège6Nathalie Bardin7Nathalie Bardin8Internal Medicine and Therapeutics department, Centre Hospitalo-Universitaire (CHU) La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceCenter for Cardiovascular and Nutrition research (C2VN), Institut national de recherche pour l'agriculture et l'alimentation (INRA) 1260, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1263, Aix-Marseille University, Marseille, FranceService d’Immunologie, Pôle de Biologie, Biogénopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceCenter for Cardiovascular and Nutrition research (C2VN), Institut national de recherche pour l'agriculture et l'alimentation (INRA) 1260, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1263, Aix-Marseille University, Marseille, FranceService d’Immunologie, Pôle de Biologie, Biogénopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceService d’Immunologie, Pôle de Biologie, Biogénopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceAix-Marseille Université, Institut de Recherche pour le Développement (IRD), Microbes, Evolution, Phylogénie et Infection (MEPHI), Institut Hospitalo-Universitaire (IHU)-Méditerranée Infection, Marseille, FranceCenter for Cardiovascular and Nutrition research (C2VN), Institut national de recherche pour l'agriculture et l'alimentation (INRA) 1260, Institut national de la santé et de la recherche médicale (INSERM) UMR_S 1263, Aix-Marseille University, Marseille, FranceService d’Immunologie, Pôle de Biologie, Biogénopole, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceIntroductionLong COVID is a public health issue with complex pathophysiology, potentially involving immunoinflammatory and prothrombotic mechanisms. Antiphospholipid antibodies (aPL) have been observed in acute COVID-19 and speculated to contribute to long COVID development. Our goal was to determine if the presence of aPL was associated with the progression towards long COVID.MethodsWe retrospectively analyzed all adult patients screened for aPL during acute COVID-19 in our institution between April 2020 and April 2022. Only patients with at least one follow-up ≥3 months post-infection were included.ResultsAmong 114 patients (median age 64.0 years, 44.7% female), 19 (16.7%) developed long COVID. Those with long COVID were younger and more frequently admitted to ICU than those who recovered. However, aPL positivity did not differ significantly between patients with and without long COVID (63.2% vs. 66.3%, p = 0.79).ConclusionOur findings suggest no association between aPL and the development of long COVID. Prior associations may reflect confounding factors such as ICU admission.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1634663/fullantiphospholipid antibodiespathophysiologyautoimmunitylong covidthrombosis |
| spellingShingle | Robin Arcani Robin Arcani Alexandre Brodovitch Xavier Heim Xavier Heim Jean-Louis Mège Jean-Louis Mège Nathalie Bardin Nathalie Bardin Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study Frontiers in Immunology antiphospholipid antibodies pathophysiology autoimmunity long covid thrombosis |
| title | Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study |
| title_full | Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study |
| title_fullStr | Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study |
| title_full_unstemmed | Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study |
| title_short | Antiphospholipid antibodies during acute COVID-19 are not associated with long COVID: findings from a retrospective cohort study |
| title_sort | antiphospholipid antibodies during acute covid 19 are not associated with long covid findings from a retrospective cohort study |
| topic | antiphospholipid antibodies pathophysiology autoimmunity long covid thrombosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1634663/full |
| work_keys_str_mv | AT robinarcani antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT robinarcani antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT alexandrebrodovitch antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT xavierheim antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT xavierheim antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT jeanlouismege antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT jeanlouismege antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT nathaliebardin antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy AT nathaliebardin antiphospholipidantibodiesduringacutecovid19arenotassociatedwithlongcovidfindingsfromaretrospectivecohortstudy |